Searchable abstracts of presentations at key conferences in endocrinology

Endocrine Abstracts

Published by BioScientifica
Previous issue | Volume 46 | UKINETS2016 | Next issue

UKI NETS 14th National Conference

Oral Communications

(1)

Table of contents

ea0046oc1 | (1) | UKINETS2016

Netazepide, a gastrin/CCK2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis

Boyce Malcolm , Moore Andrew , Parsons Bryony , Lloyd Katie , Sagatun Liv , Thomsen Liv , Varro Andrea , Fossmark Reidar , Waldum Helge , Pritchard David M

Introduction: In a two-centre, 12-week, open trial in 16 patients with autoimmune chronic atrophic gastritis, hypergastrinaemia, multiple type 1 gastric neuroendocrine tumours (NETs), and raised circulating CgA, the gastrin/CCK2 receptor antagonist (CCK2RA), netazepide, reduced the tumour number and size, and normalised CgA.Aim(s): To treat those patients with netazepide for longer, and to identify new biomarkers.Materials and meth...
0 shares

ea0046oc2 | (1) | UKINETS2016

Tumour size is not a reliable criterion for management of patients with Non-secreting pancreatic neuroendocrine tumours: results of a large, multi-centre, operative cohort

Mills Logan , Drymousis Panagiotis , Vashist J , Burdelski C , Prachalias Andreas , Srinivasan Parthi , Menon Krishna , Khan Saboor , Cave Judith , Armstrong Thomas , Weickert MO , Frilling Andreja , Ramage JK , Srirajaskanthan Raj

Background: Small pancreatic neuroendocrine tumours (PNETs) present a management dilemma because of their uncertain natural history. Some clinicians believe that lesions <2 cm are indolent and can be managed with surveillance. By contrast, the most recent WHO classification system regards all PNETs as potentially malignant.Aim: To assess the malignant behaviour of small PNETs in a large, retrospective, multicentre patient cohort.<p class="abstext...
0 shares

ea0046oc3 | (1) | UKINETS2016

Efficacy and safety of telotristat etiprate in patients with carcinoid syndrome not adequately controlled by somatostatin analog therapy: Analysis of the ongoing TELESTAR extension period

Horsch D , Kulke M , Caplin M , Anthony L , Bergsland E , Oberg K , Welin S , Warner R , Lombard-Bohas C , Kunz P , Valle J , Fleming D , Lapuerta P , Banks P , Pavel M

Introduction: TELESTAR was a pivotal, randomized phase 3 study evaluating telotristat etiprate (TE), a tryptophan hydroxylase inhibitor, among patients (pts) with carcinoid syndrome (CS). When added to somatostatin analogues (SSA), 250 mg tid and 500 mg tid TE each produced significantly greater bowel movement (BM) frequency reduction averaged over 12 weeks (wks) than placebo (PBO) plus SSA (P<0.001). Pts crossed over to open-label (OL) treatment with TE 500 mg ti...
0 shares

Published by BioScientifica

Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more